Peg-IFNα-2a Contributed to HBs Antigen Seroclearance in a Patient with Chronic Hepatitis B Administered Nucleic Acid Analogs: A Three-year Follow-up

Intern Med. 2021 Jun 15;60(12):1835-1838. doi: 10.2169/internalmedicine.5783-20. Epub 2021 Jan 15.

Abstract

We treated a 51-year-old Japanese man with chronic hepatitis B (viral load 7.6 LC/mL, genotype C). Hepatitis B virus DNA and HBe antigen were undetectable during the administration of the nucleic acid analogs (NUCs) lamivudine and adefovir, although the concentration of HBs antigen (HBsAg) was 851.2 IU/mL. The HBsAg levels were reduced 150-fold when pegylated-interferon (Peg-IFN) α-2a was administered weekly for 48 weeks and did not increase during the rest period. Therefore, Peg-IFNα-2a was administered twice each week. During this time, HBsAg reached undetectable concentrations, and HBs antibody was detected and continued to be detectable during the three-year follow-up. These unprecedented findings suggest that IFN may contribute to the seroclearance of HBsAg in patients treated with NUCs.

Keywords: HBs antibody; HBs antigen; case reports; chronic hepatitis B; interferon.

Publication types

  • Case Reports

MeSH terms

  • Antiviral Agents / therapeutic use
  • DNA, Viral
  • Follow-Up Studies
  • Hepatitis B Surface Antigens
  • Hepatitis B e Antigens
  • Hepatitis B virus / genetics
  • Hepatitis B, Chronic* / drug therapy
  • Humans
  • Male
  • Middle Aged
  • Nucleic Acids* / therapeutic use
  • Polyethylene Glycols / therapeutic use
  • Recombinant Proteins / therapeutic use

Substances

  • Antiviral Agents
  • DNA, Viral
  • Hepatitis B Surface Antigens
  • Hepatitis B e Antigens
  • Nucleic Acids
  • Recombinant Proteins
  • Polyethylene Glycols